Evofem biosciences, inc. (EVFM)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

8,785

15,571

32,100

50,679

184

1,330

12,076

22,788

5,029

1,211

5,750

7,588

9,749

-

14,363

21,471

24,089

37,748

51,270

62,954

70,717

75,947

Cash

-

-

-

-

-

-

-

-

-

-

-

-

-

10,937

-

-

-

-

-

-

-

-

Restricted Cash, Current

480

304

386

401

416

431

446

554

569

490

-

-

-

550

-

-

-

-

-

-

-

-

Debt Securities, Held-to-maturity

1,486

8,233

3,715

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and other current assets

2,966

2,313

1,311

1,769

813

717

902

1,133

1,608

653

380

502

853

781

509

757

1,075

1,976

995

815

761

925

Total current assets

13,717

26,421

37,532

52,849

1,413

2,478

13,424

24,475

7,206

2,354

6,130

8,090

10,603

12,268

14,873

22,229

25,165

39,725

52,266

63,770

71,479

76,873

Restricted cash

-

-

-

-

-

-

-

-

-

-

93

-

-

-

-

-

-

200

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

93

93

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

200

200

-

200

200

200

-

Property, Plant and Equipment, Net

622

394

546

461

527

593

652

717

783

848

22

29

36

1,086

132

150

168

186

204

221

240

24

Operating lease right-of-use assets

262

160

300

483

645

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other noncurrent assets

1,044

1,320

596

622

649

939

950

977

1,003

750

-

-

-

1,017

-

-

-

-

-

-

-

-

Total assets

15,645

28,295

38,989

54,415

3,234

4,010

15,026

26,169

8,992

3,952

6,246

8,213

10,733

14,371

15,205

22,580

25,533

40,111

52,670

64,192

71,920

76,898

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

7,120

6,008

5,163

8,567

11,933

8,882

8,034

7,998

13,309

8,999

410

548

955

2,015

797

1,090

1,420

4,017

6,413

2,991

1,897

997

Note payable

-

-

0

0

4,010

4,010

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical trial expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71

489

630

1,422

-

-

-

-

Accrued severance

-

-

-

-

-

-

-

-

-

-

191

-

-

-

-

-

-

-

-

-

-

-

Other accrued expenses, other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

903

-

-

-

-

Other accrued expenses

-

-

-

-

-

-

-

-

-

-

794

1,151

742

-

563

961

1,038

-

-

-

-

912

Accrued Liabilities, Current

2,499

2,784

6,453

7,217

11,646

11,513

14,447

11,104

12,587

12,086

-

-

-

5,337

-

-

-

-

3,603

1,761

1,590

-

Accrued compensation

4,739

3,670

2,916

2,259

3,724

2,924

2,561

1,738

1,138

2,392

-

-

-

1,617

-

-

-

-

-

-

-

-

Operating lease liabilities- current

103

197

382

580

772

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series D 2X liquidation preference

-

-

-

-

-

-

0

0

0

79,870

-

-

-

8,030

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

9

-

-

Long-term debt, current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,190

785

2,756

1,986

1,228

487

-

Total current liabilities

14,461

12,659

14,914

18,623

32,085

27,329

25,042

20,840

27,034

103,347

1,396

1,700

1,697

16,999

1,431

3,732

3,874

9,099

12,021

5,990

3,976

1,909

Operating lease liabilities- noncurrent

163

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

0

0

0

37

49

71

92

114

-

-

-

172

-

-

-

-

-

-

-

-

Other noncurrent liabilities

-

-

-

-

-

-

0

0

158

166

-

-

-

213

-

-

-

-

-

-

-

-

Total liabilities

14,624

12,659

14,914

18,623

32,085

27,366

25,091

20,911

27,284

103,627

-

-

-

17,384

-

-

-

-

-

-

-

-

Commitments and contingencies (Note 6)

-

-

-

-

-

-

0

0

0

-

-

-

-

0

-

-

-

-

-

-

-

-

Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding

0

0

-

-

-

0

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term debt, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,809

3,154

7,205

7,916

8,616

9,300

9,741

Stockholders’ equity:
Common stock, $0.0001 par value; 300,000,000 shares authorized; 49,642,097 and 48,137,880 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively;

5

5

5

5

3

3

3

3

2

0

1

1

1

81

1

1

1

1

1

1

1

1

Additional paid-in capital

533,341

528,810

524,532

522,451

422,360

409,787

408,097

404,989

358,196

17,731

138,332

138,189

137,898

20,806

137,651

137,552

137,361

136,637

136,047

135,637

135,219

134,920

Accumulated deficit

-532,300

-513,179

-500,500

-486,664

-451,200

-433,146

-418,165

-399,734

-376,490

-307,277

-133,484

-131,677

-128,863

-201,972

-123,878

-121,515

-118,858

-112,831

-103,316

-86,054

-76,577

-69,674

Total stockholders’ equity

1,021

15,636

24,075

35,792

-28,851

-23,356

-10,065

5,258

-18,292

-289,546

4,849

6,512

9,035

-181,085

13,774

16,038

18,504

23,807

32,732

49,584

58,644

65,247

Total liabilities and stockholders’ equity

15,645

28,295

38,989

54,415

3,234

4,010

15,026

26,169

8,992

3,952

6,246

8,213

10,733

14,371

15,205

22,580

25,533

40,111

52,670

64,192

71,920

76,898

Series A Convertible Preferred Stock
Convertible preferred stock, value

-

-

-

-

-

-

-

-

-

23,848

-

-

-

-

-

-

-

-

-

-

-

-

Series B Convertible Preferred Stock
Convertible preferred stock, value

-

-

-

-

-

-

-

-

-

43,616

-

-

-

-

-

-

-

-

-

-

-

-

Series C-1 Convertible Preferred Stock
Convertible preferred stock, value

-

-

-

-

-

-

-

-

-

34,382

-

-

-

-

-

-

-

-

-

-

-

-

Series C Convertible Preferred Stock
Convertible preferred stock, value

-

-

-

-

-

-

-

-

-

19,469

-

-

-

-

-

-

-

-

-

-

-

-

Series D Convertible Preferred Stock
Convertible preferred stock, value

-

-

-

-

-

-

-

-

-

68,556

-

-

-

-

-

-

-

-

-

-

-

-